Physical, Chemical and Biological Targeting in Radiation Oncology: 7th International Conference on Dose, Time and Fractionation in Radiation Oncology

Physical, Chemical and Biological Targeting in Radiation Oncology: 7th International Conference on Dose, Time and Fractionation in Radiation Oncology

Author:  Minesh Mehta, Bhudatt R. Paliwal, and Soren M. Bentzen, editors
ISBN:  9781888340532      ISBN10:  1888340533
Published:  2006 | 341 pp. | 


OUT OF PRINT







Table of Contents

Contents

Section I: Perspectives
Biological Basis for Targeting in Radiation Oncology, Søren M. Bentzen, Ph.D., D.Sc.
Modern Radiotherapy Tools, Bhudatt R. Paliwal, Ph.D.

Section II: Chemical/Biological Targeting
Combining Angiogenesis Inhibitors With Radiation, Deborah Citrin, M.D., Robert J. Surawski, B.A., and Kevin Camphausen, M.D.
Combining EGFR Inhibitors With Radiation, Paul Harari, M.D.
Targeting DNA-dsb Repair To Improve Radiotherapy Outcome, Robert Glen Bristow, M.D., Ph.D., F.R.C.P.C

Section III: Keynote Lecture
Chemo-Radiotherapy: Any Real Progress?, Ian F. Tannock, M.D., Ph.D.

Section IV: Improved Targeting of Radiation
Development of Biologically Optimized Light Ion Therapy Using the BIO-ART Approach, Anders Brahme, Ph.D.
Will Image-Guided Radiotherapy Improve Outcome?, Wolfgang A. Tomé, Ph.D.
Review of Uncertainties in Intensity-Modulated Radiation Therapy (IMRT), T. R. Mackie, Ph.D., R. T. Flynn, M.W. Kissick, Ph.D., R. Jeraj, Ph.D., and G. H. Olivera, Ph.D.
Reducing Organ Motion, Laura A. Dawson, M.D.

Section V: Proffered Papers
Volume Analysis of Intracranial Metastatic Tumors, Steven J. Goetsch, Ph.D., Prabakhar Tripuraneni, M.D., David Hodgens, M.D., Kenneth Ott, M.D., and John Alksne, M.D.
Intensity-Modulated Radiation Therapy Dose Eye Views, Peter Metcalfe, Ph.D., P. Tangboonduangjit, M. Williams, M. Carolan, and M. Butson
Integral Dose in Pediatric Craniospinal Irradiation with the Helical Tomotherapy Hi-ART System, José A. Peñagarícano, M.D., Chengyu Shi, Ph.D., and Vaneerat Ratanatharathorn, M.D.
Radiobiological Considerations in the Choice of the Reference Dose Level from DVH Evaluation, Valeria Landoni, Ph.D.
Optimization of the Temporal Pattern of Radiation Delivery in IMRT, Michael B. Altman, B.A., Joseph O. Deasy, Ph.D., Steven J. Chmura, M. D., Ph.D., and John C. Roeske, Ph.D.
Dosimetric Impact of Setup Uncertainty in Gynecology Patients Receiving Intensity Modulated Pelvic Radiotherapy (IM-PRT), Joshua J. Haslam, B.S., Arno J. Mundt, M.D., and John C. Roeske, Ph.D.
Influence of Acute Tumor Hypoxia on Radiation Therapy Outcome, Iuliana Toma-Daşu, Ph.D., Alexandru Daşu, Ph.D., and Anders Brahme, Ph.D.

Section VI: Clinical and Pre-Clinical Approaches
How Do We Apply Emerging Clinical Data and Where Do We Go Next in the Management of Head and Neck Carcinoma?, Kian Ang, M.D., Ph.D.
IMRT/Tomotherapy in Prostate Cancer, Patrick Kupelian, M.D.
Translational Research Using Dogs with Spontaneous Tumors, Lisa J. Forrest, V.M.D.

Section VII: Proffered Papers
Modulation of Dose Rate Effects: Implications for Retreatment with Ionizing Irradiation with Minimization of Normal Neural Tissue Toxicity While Maximizing Tumor Control Probability, Steven Howard, M.D., Ph.D., H. Ian Robins, M.D., Ph.D., James Welsh, M.D., Wolfgang Tomé, Ph.D.
Acute Toxicity Following Hypofractionated Conformal Radiotherapy of Localized Prostate Cancer. A Nonrandomized Contemporary Comparison with Standard Fractionation, Felix Leborgne, M.D., and Jack Fowler, D.Sc., Ph.D.
Continuous Accelerated Radiotherapy in 7 Days Versus 5 Days a Week for Head and Neck Cancer (CAIR-I and CAIR-II Trials), Bogusçaw Maciejewski, M.D., Ph.D., Kryzstof Składowski, M.D., Ph.D., and Andrzej Wygoda, M.D.
Preliminary Results of Accelerated Hyperfractionated Split-Course Radiotherapy (CHA-CHA) of Advanced Head and Neck Cancers, Leszek Miszczyk, M.D., Ph.D, G. Woźniak, B. Maciejewski, R. Tarnawski, and R. Suwiński
Randomized Clinical Trial on Continuous 7-Days-A-Week Postoperative Radiotherapy for Head and Neck Cancer: An Interim Report on Acute Normal Tissue Reactions, Rafał Suwiński, M.D., Ph.D., M. Bankowska-Woźniak, W. Majewski, A. Sowa, A. Idasiak, E. Ziolkowska, W. Windorbska, R. Tarnawski, L. Miszczyk, K. Składowski, and B. Maciejewski
Changes of Brain Metabolism Revealed by Magnetic Resonance Spectroscopy in vivo Are Correlated with Irradiated Volume, Rafał Tarnawski, Ph.D., and Tomasz Rutkowski
Minimally Invasive Intraoperative Radiotherapy (MIR): A Novel IORT Alternative, Alonso N. Gutiérrez, M.S., S. M. Murphy, L. J. Forrest, D. Bjorling, and T. R. Mackie
Machine Learning Methods for Radiobiological Outcomes Modeling, Issam El Naqa, Ph.D., Jeffrey D. Bradley, and Joseph O. Deasy, Ph.D.

Section VIII: Statistical Methods Workshop
Phase I Trial Designs for Radiotherapy, Richard Chappell, Ph.D.

Section IX: Clinical Perspectives
Target Volume Definition: The Increasing Role of Functional Imaging, Vincent Gregoire, M.D., Ph.D.
Estimating Tumor Control Probability in the Era of GTV, CTV, PTV, ITV, 4D-CT, and IGRT, Andrzej Niemierko, Ph.D.
Gliomas: Setting New Standards and Developing New Therapeutic Approaches, Minesh Mehta, M.D.
Phase I/II Trial of Dose-Per-Fraction Escalation for Prostate Cancer, Mark A. Ritter, M.D., Ph.D., Richard J. Chappell, Ph.D., Jack F. Fowler, D.Sc., Ph.D.,Wolfgang A. Tomé, Ph.D., and Patrick A. Kupelian, M.D.

Section X: Molecular and Functional Imaging
The Use of Radiologic Imaging in the Assessment of Radiation-Induced Normal Tissue Injury, Elizabeth S. Evans, B.S., Zafer Kocak, M.D., Su-Min Zhou, Ph.D., and Lawrence B. Marks, M.D.
Imaging Hypoxia, C. Clifton Ling, Ph.D.
Functional Imaging of Treatment Response During Radiotherapy, Robert Jeraj, Ph.D., Dave Barbee, Elizabeth M. Smith, Jerry Nickles, Onofre T. DeJesus, David W. Dick, Elizabeth A. Ballegeer, and Lisa J. Forrest, V.M.D.
Tumor Subvolume Dose Escalation: To Paint or Not to Paint, Is that the Question?, Steve P. Lee, M.D., Ph.D., and H. Rodney Withers, M.D., D.Sc.

Section XI: Dose-Volume Modeling
Volume Effects in Spinal Cord, Albert J. van der Kogel, Ph.D.
Dose-Volume Modeling of Xerostomia in Patients with Head and Neck Cancer Receiving Radiation Therapy, Joseph O. Deasy, Ph.D., Angel I. Blanco, M.D., and Issam El Naqa, Ph.D.
Use of the Break Pair Model for Radiation-induced Cell Killing in the EKP Formula, Richard A. Morrison, M.D., F.A.C.R., F.A.C.R.O.
The Break Pair Model for Radiation-induced Cell Killing at Low Dose Rates, Richard A. Morrison, M.D., F.A.C.R., F.A.C.R.O.
The Break Pair Model for Radiation-induced Cell Killing When There Is Incomplete Repair of Sublethal Injury, Richard A. Morrison, M.D., F.A.C.R., F.A.C.R.O.
Predicting Symptomatic Radiation-Induced Pneumonitis, Jingfang Mao, M.D., Zafer Kocak, M.D., Ph.D., Sumin Zhou, Ph.D., Rodney J. Folz, M.D., Elizabeth S. Evans, B.S., Mitchell S. Anscher, M.D., Jing Zeng, B.S., and Lawrence B. Marks, M.D.
Radiation Pneumonitis Risk Based on Clinical, Dosimetric, and Location Related Factors, Joseph O. Deasy, Ph.D., Andrew J. Hope, Patricia E. Lindsay, Ph.D., Issam El Naqa, Ph.D., and Jeffrey D. Bradley
Statistical Analysis of Clinical Complication Data. The Rubin-Casarett Clinicopathological Schema: Jump-Enhanced Stochastic Processes and Stochastic Bifurcations, Donald Herbert, Ph.D.
Is There an Optimum Head and Neck Radiotherapy Schedule?, Jack F. Fowler, D.Sc., Ph.D.